135 related articles for article (PubMed ID: 37865969)
1. Incorporating mutations and bone marrow fibrosis into the revised international prognostic scoring system in myelodysplastic syndromes.
Zhao Y; Guo J; Zhao S; Wang R; Wu D; Chang C
Leuk Lymphoma; 2024 Jan; 65(1):100-108. PubMed ID: 37865969
[TBL] [Abstract][Full Text] [Related]
2. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.
Melody M; Al Ali N; Zhang L; Ramadan H; Padron E; Sallman D; Sweet K; Lancet J; List A; Bennett JM; Komrokji R
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):324-328. PubMed ID: 32044274
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update.
Jain AG; Zhang L; Bennett JM; Komrokji R
Ann Lab Med; 2022 May; 42(3):299-305. PubMed ID: 34907099
[TBL] [Abstract][Full Text] [Related]
4. A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort study.
GenoMed4All consortium
Lancet Haematol; 2023 Feb; 10(2):e117-e128. PubMed ID: 36436542
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.
Nazha A; Narkhede M; Radivoyevitch T; Seastone DJ; Patel BJ; Gerds AT; Mukherjee S; Kalaycio M; Advani A; Przychodzen B; Carraway HE; Maciejewski JP; Sekeres MA
Leukemia; 2016 Nov; 30(11):2214-2220. PubMed ID: 27311933
[TBL] [Abstract][Full Text] [Related]
6. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
7. A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS.
Gu S; Xia J; Tian Y; Zi J; Ge Z
BMC Cancer; 2021 Feb; 21(1):134. PubMed ID: 33549060
[TBL] [Abstract][Full Text] [Related]
8. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
9. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
[TBL] [Abstract][Full Text] [Related]
10. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
Bejar R; Stevenson KE; Caughey BA; Abdel-Wahab O; Steensma DP; Galili N; Raza A; Kantarjian H; Levine RL; Neuberg D; Garcia-Manero G; Ebert BL
J Clin Oncol; 2012 Sep; 30(27):3376-82. PubMed ID: 22869879
[TBL] [Abstract][Full Text] [Related]
11. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.
Aguirre LE; Al Ali N; Sallman DA; Ball S; Jain AG; Chan O; Tinsley-Vance SM; Kuykendall A; Sweet K; Lancet JE; Padron E; Komrokji RS
Leukemia; 2023 Jul; 37(7):1530-1539. PubMed ID: 37147425
[TBL] [Abstract][Full Text] [Related]
12. Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes.
Xiong B; Nie Y; Tang Z; Xue M; Zuo X
Pathology; 2017 Aug; 49(5):526-533. PubMed ID: 28669578
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Molecular International Prognostic Scoring System (M-IPSS) and Revised International Prognostic Scoring System (R-IPSS) in Thai patients with myelodysplastic neoplasms.
Polprasert C; Niparuck P; Rattanathammethee T; Kobbuaklee S; Lanamtieng T; Rojnuckarin P
Hematology; 2022 Dec; 27(1):1301-1304. PubMed ID: 36519260
[TBL] [Abstract][Full Text] [Related]
14. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
15. [Molecular international prognostic scoring system for myelodysplastic syndromes].
Nagata Y
Rinsho Ketsueki; 2023; 64(5):355-368. PubMed ID: 37271526
[TBL] [Abstract][Full Text] [Related]
16. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
[TBL] [Abstract][Full Text] [Related]
17. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
Sauta E; Robin M; Bersanelli M; Travaglino E; Meggendorfer M; Zhao LP; Caballero Berrocal JC; Sala C; Maggioni G; Bernardi M; Di Grazia C; Vago L; Rivoli G; Borin L; D'Amico S; Tentori CA; Ubezio M; Campagna A; Russo A; Mannina D; Lanino L; Chiusolo P; Giaccone L; Voso MT; Riva M; Oliva EN; Zampini M; Riva E; Nibourel O; Bicchieri M; Bolli N; Rambaldi A; Passamonti F; Savevski V; Santoro A; Germing U; Kordasti S; Santini V; Diez-Campelo M; Sanz G; Sole F; Kern W; Platzbecker U; Ades L; Fenaux P; Haferlach T; Castellani G; Della Porta MG
J Clin Oncol; 2023 May; 41(15):2827-2842. PubMed ID: 36930857
[TBL] [Abstract][Full Text] [Related]
18. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.
de Swart L; Smith A; Johnston TW; Haase D; Droste J; Fenaux P; Symeonidis A; Sanz G; Hellström-Lindberg E; Cermák J; Germing U; Stauder R; Georgescu O; MacKenzie M; Malcovati L; Holm MS; Almeida AM; Mądry K; Slama B; Guerci-Bresler A; Sanhes L; Beyne-Rauzy O; Luño E; Bowen D; de Witte T
Br J Haematol; 2015 Aug; 170(3):372-83. PubMed ID: 25907546
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
20. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.
Lee WH; Tsai MT; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Liu MC; Yang YT; Chen JC; Tang JL; Sun HI; Chuang YK; Lin LI; Chou WC; Lin CC; Hou HA; Tien HF
Blood Cancer J; 2023 Aug; 13(1):120. PubMed ID: 37558665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
